DGIdb - REGORAFENIB Drug Record

REGORAFENIB chembl:CHEMBL1946170 ApprovedAntineoplastic

Alternate Names:

REGORAFENIB
BAY-734506 MONOHYDRATE
STIVARGA
BAY-73-4506
BAY-734506
RÉGORAFÉNIB
STIVARGA®
REGORAFENIBUM
BAY 73-4506
chemidplus:755037-03-7
drugbank:08896
chembl:CHEMBL1946170
rxcui:1312397
pubchem.compound:11167602

Drug Info:

FDA Approval	not approved
Drug Class	small molecule
Drug Indications	antineoplastic agent
FDA Approval	Colorectal cancer, Gastrointestinal stromal tumors
Drug Class	Kinase Inhibitors

(9 More Sources)

Publications:

Wilhelm et al., 2011, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity., Int. J. Cancer
Martinelli et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int. J. Cancer
Napolitano et al., 2015, Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab., Clin. Cancer Res.
Ben-Ami et al., 2016, Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy., Ann. Oncol.
Garner et al., 2014, Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients., Clin. Cancer Res.
Loaiza-Bonilla et al., 2016, KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer., Cureus
Kollàr et al., 2014, Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program., Clin Sarcoma Res
Tong J et al., 2017 Feb 9, FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation., Oncogene

REGORAFENIB DDR2

Interaction Score: 0.88

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Discoidin domain-containing receptor 2 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB FBXW7

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
27399335

Sources:
JAX-CKB
REGORAFENIB TEK

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name regorafenib, BAY 73-4506

Novel drug target Novel Target

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB KIT

Interaction Score: 0.4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type decreased response

Approval Status Preclinical - Cell culture

Approval Status Phase II

PMIDs:
21170960 27371698 25239608

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC MyCancerGenomeClinicalTrial TTD OncoKB
REGORAFENIB RAF1

Interaction Score: 0.35

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase RAF inhibitor

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB VHL

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type renal cell carcinoma

Response Type predicted – sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
21170960

Sources:
JAX-CKB
REGORAFENIB ARAF

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
REGORAFENIB RET

Interaction Score: 0.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Tyrosine-protein kinase receptor RET inhibitor

Direct Interaction yes

PMIDs:
21170960

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial TTD
REGORAFENIB APC

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Clinical Study

PMIDs:
27004155

Sources:
JAX-CKB
REGORAFENIB MAPK11

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction MAP kinase p38 beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB BRAF

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase B-raf inhibitor

Indication/Tumor Type colorectal cancer

PMIDs:
21170960 23629727 25838391

Sources:
MyCancerGenome JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB FRK

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase FRK inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB NRAS

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
23629727 25838391

Sources:
JAX-CKB
REGORAFENIB KDR

Interaction Score: 0.14

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name regorafenib, BAY 73-4506

Novel drug target Established target

Indication/Tumor Type colorectal cancer

PMIDs:
27004155

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial TTD
REGORAFENIB PDGFRA

Interaction Score: 0.14

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Indication/Tumor Type gastrointestinal stromal tumor

PMIDs:
25905001

Sources:
JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB KRAS

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type breast cancer

Approval Status Preclinical - Cell line xenograft

Approval Status Preclinical - Cell culture

PMIDs:
21170960 23629727 27004155 25838391

Sources:
JAX-CKB MyCancerGenomeClinicalTrial PharmGKB OncoKB
REGORAFENIB EPHA2

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
REGORAFENIB PDGFRB

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB FLT1

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB FLT4

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB FGFR2

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor 2 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB VEGFA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
REGORAFENIB FGFR1

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial
REGORAFENIB PIK3CA

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
23629727 25838391

Sources:
JAX-CKB
REGORAFENIB NTRK1

Interaction Score: 0.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
REGORAFENIB EGFR

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + Regorafenib

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
23629727

Sources:
JAX-CKB PharmGKB
REGORAFENIB ABL1

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
REGORAFENIB YES1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

MyCancerGenome: REGORAFENIB
- Version: 20-Jun-2017
Alternate Names:

REGORAFENIB Generic Name

STIVARGA Trade Name

Drug Info:

Drug Class Kinase Inhibitors

FDA Approval Colorectal cancer, Gastrointestinal stromal tumors

Publications:
TdgClinicalTrial: REGORAFENIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:

JAX-CKB: Regorafenib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Wilhelm et al., 2011, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity., Int. J. Cancer

Ben-Ami et al., 2016, Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy., Ann. Oncol.

Garner et al., 2014, Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients., Clin. Cancer Res.

CIViC: REGORAFENIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Ben-Ami et al., 2016, Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy., Ann. Oncol.

Garner et al., 2014, Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients., Clin. Cancer Res.

TALC: REGORAFENIB
- Version: 12-May-2016
Alternate Names:

REGORAFENIB Primary Drug Name

REGORAFENIB Drug Generic Name

STIVARGA Drug Trade Name

Drug Info:

Publications:
DTC: REGORAFENIB
- Version: 02-September-2020
Alternate Names:

CHEMBL1946170 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Regorafenib
- Version: 2020.06.01
Alternate Names:

D09GDD TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1946170
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: REGORAFENIB
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1946170
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Regorafenib
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
OncoKB: Regorafenib
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
PharmGKB: regorafenib
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Discoidin domain-containing receptor 2 inhibitor
Direct Interaction	yes

Indication/Tumor Type	colorectal cancer
Response Type	resistant
Approval Status	Preclinical - Cell culture

Trial Name	regorafenib, BAY 73-4506
Novel drug target	Novel Target
Notes

Response Type	decreased response
Approval Status	Preclinical - Cell culture
Approval Status	Phase II

Direct Interaction	yes
Mechanism of Interaction	Serine/threonine-protein kinase RAF inhibitor

Indication/Tumor Type	renal cell carcinoma
Response Type	predicted – sensitive
Approval Status	Preclinical - Cell line xenograft

Notes
Mechanism of Interaction	Tyrosine-protein kinase receptor RET inhibitor
Direct Interaction	yes

Mechanism of Interaction	MAP kinase p38 beta inhibitor
Direct Interaction	yes

Direct Interaction	yes
Mechanism of Interaction	Serine/threonine-protein kinase B-raf inhibitor
Indication/Tumor Type	colorectal cancer

Mechanism of Interaction	Tyrosine-protein kinase FRK inhibitor
Direct Interaction	yes

Direct Interaction	yes
Mechanism of Interaction	Platelet-derived growth factor receptor inhibitor
Indication/Tumor Type	gastrointestinal stromal tumor

Indication/Tumor Type	breast cancer
Approval Status	Preclinical - Cell line xenograft
Approval Status	Preclinical - Cell culture

Direct Interaction	yes
Mechanism of Interaction	Vascular endothelial growth factor receptor inhibitor
Notes

Mechanism of Interaction	Fibroblast growth factor receptor 2 inhibitor
Direct Interaction	yes

Mechanism of Interaction	Fibroblast growth factor receptor 1 inhibitor
Direct Interaction	yes

combination therapy	Pimasertib + Regorafenib
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive

Mechanism of Interaction	Tyrosine-protein kinase ABL inhibitor
Direct Interaction	yes

REGORAFENIB	Primary Drug Name
REGORAFENIB	Drug Generic Name
STIVARGA	Drug Trade Name

REGORAFENIB Drug Record

REGORAFENIB chembl:CHEMBL1946170 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Discoidin domain-containing receptor 2 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type resistant Approval Status Preclinical - Cell culture

PMIDs: 27399335

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name regorafenib, BAY 73-4506 Novel drug target Novel Target Notes

PMIDs: None found

Sources: TALC TdgClinicalTrial ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Response Type decreased response Approval Status Preclinical - Cell culture Approval Status Phase II

PMIDs: 21170960 27371698 25239608

Sources: TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC MyCancerGenomeClinicalTrial TTD OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Serine/threonine-protein kinase RAF inhibitor

PMIDs: None found

Sources: MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type renal cell carcinoma Response Type predicted – sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 21170960

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Mechanism of Interaction Tyrosine-protein kinase receptor RET inhibitor Direct Interaction yes

PMIDs: 21170960

Sources: TALC MyCancerGenome JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial TTD

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type sensitive Approval Status Clinical Study

PMIDs: 27004155

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction MAP kinase p38 beta inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Serine/threonine-protein kinase B-raf inhibitor Indication/Tumor Type colorectal cancer

PMIDs: 21170960 23629727 25838391

Sources: MyCancerGenome JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase FRK inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type resistant Approval Status Preclinical

PMIDs: 23629727 25838391

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name regorafenib, BAY 73-4506 Novel drug target Established target Indication/Tumor Type colorectal cancer

PMIDs: 27004155

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Indication/Tumor Type gastrointestinal stromal tumor

PMIDs: 25905001

Sources: JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type breast cancer Approval Status Preclinical - Cell line xenograft Approval Status Preclinical - Cell culture

PMIDs: 21170960 23629727 27004155 25838391

Sources: JAX-CKB MyCancerGenomeClinicalTrial PharmGKB OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes Notes

PMIDs: None found

Sources: TALC MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor Notes

PMIDs: None found

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Discoidin domain-containing receptor 2 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
27399335

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name regorafenib, BAY 73-4506

Novel drug target Novel Target

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type decreased response

Approval Status Preclinical - Cell culture

Approval Status Phase II

PMIDs:
21170960 27371698 25239608

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC MyCancerGenomeClinicalTrial TTD OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase RAF inhibitor

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type renal cell carcinoma

Response Type predicted – sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
21170960

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Tyrosine-protein kinase receptor RET inhibitor

Direct Interaction yes

PMIDs:
21170960

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Clinical Study

PMIDs:
27004155

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction MAP kinase p38 beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serine/threonine-protein kinase B-raf inhibitor

Indication/Tumor Type colorectal cancer

PMIDs:
21170960 23629727 25838391

Sources:
MyCancerGenome JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase FRK inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
23629727 25838391

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name regorafenib, BAY 73-4506

Novel drug target Established target

Indication/Tumor Type colorectal cancer

PMIDs:
27004155

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Indication/Tumor Type gastrointestinal stromal tumor

PMIDs:
25905001

Sources:
JAX-CKB ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type breast cancer

Approval Status Preclinical - Cell line xenograft

Approval Status Preclinical - Cell culture

PMIDs:
21170960 23629727 27004155 25838391

Sources:
JAX-CKB MyCancerGenomeClinicalTrial PharmGKB OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor 2 inhibitor

Direct Interaction yes